Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 138 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... September 4, 2018 FDA Approves Lazertinib with Amivantamab-vmjw for Locally Advanced or Metastatic NSCLC... September 9, 2024 Trial Should Change Care for AIDS-Related Kaposi Sarcoma in Sub-Saharan Africa March 10, 2020 Treating the Whole Person: How Cancer Centers Are Addressing Social Needs July 18, 2024 Load more HOT NEWS Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer Aiming to support a robust regulatory ecosystem for driving cancer research... 24-Year-Old Woman with Terminal Breast Cancer Dreams of Fairytale Wedding with... Lack of Evidence for the Use of Telemedicine in the Prevention...
